Amebiasis: Importance of the diagnosis and treatment. Minireview;Amibiasis: Importancia de su diagnóstico y tratamiento. Mini-revision

Investigacion Clinica

Volumn 49, Issue 2, 2008, Pages 265-271

  Araujo, José ^a   García, María Eugenia ^a   Díaz Suárez, Odelis ^a   Urdaneta, Haidee ^b  

^a UNIVERSIDAD DEL ZULIA   (Venezuela)

^b Universidad De Los Andes Facultad de Medicina   (Venezuela)

Author keywords

Amebiasis; Diagnosis; Pathogenic strains; Treatment

Indexed keywords

ANTIAMEBIC AGENT;

AMEBIASIS; ELECTROPHORESIS; ENTAMOEBA HISTOLYTICA; GENOTYPE; HUMAN; PARASITE VIRULENCE; PATHOGENESIS; POLYMERASE CHAIN REACTION; SHORT SURVEY; VENEZUELA;

AMEBICIDES; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; DNA, PROTOZOAN; ENTAMOEBA HISTOLYTICA; ENTAMOEBIASIS; GENOME; HUMANS; INCIDENCE; PARASITOLOGY; POLYMERASE CHAIN REACTION; SPECIES SPECIFICITY;

EID: 49449109242     PISSN: 05355133     EISSN: 05355133     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (43)

1. World Health Organitation (WHO). A consultation with experts on amibiasis. Epidem Bull PAHO 1997; 18:13-14.
2. Walsh JA. Problems in recognition and diagnosis of amebiasis: examination of the global magnitude of morbity and mortally. Rev Infect Dis 1986; 8:228-238.
3. Britten D, Wilson S, Mcnerney R, Moody A, Chiodini L, Ackers J. An improved colorimetric PGR-based for detection and differentiation of Entamoeba histolytica and Entamoeba dispar in feces. J Clin Microbiol 1997; 35:1108-1111.
4. Diamond L, Clark G. A redescription of Entamoeba histolytica Shaudinn, 1903 (Emended Walker 1911) separating it from Entamoeba dispar Brumpt, 1925. J Euk Microbiol 1993; 40:340-344.
5. Gomes M, Pesquero J, Furst C, Valle P, Silva F. An improved method to distinguish Entamoeba histolytica and Entamoeba dispar. Parasitol 1999; 119: 359-362.
6. World Health Organization WHO/PAHO informal consultation on intestinal protozoal infections. 21-23 de octubre. Oaxtepec, México. 1991. p: 5-10.
7. Jackson T. Entamoeba histolytica and Entamoeba dispar are distinct species, clinical, epidemiological and serological evidence. Int J Parasitol 1998; 28:181-186.
8. Haque R, Ali I, Akther S y Petri J. Gomparision of PCR, isoenzyme analysis and antigen detection for diagnosis of Entamoeba histolytica infection. J of Clin Microbiol 1999; 36:449-452.
9. Blanc DS. Determination of taxonomic status of pathogenic and non-pathogenic Entamoeba histolytica zymodemes using isoenzyme analysis. J Protozool 1992; 39: 471-479.
10. Clark C, Diamond LS. Ribosomal genes of "pathogenic" and "non-pathogenic" Entamoeba histolytica are distinct. Mol Biochem Parasitol 1991; 49:297-302.
11. Cruz-Reyes J, Spice WM, Rehman T, Gisborne E, Ackers J. Ribosomal DNA sequences in the differentiation of pathogenic and non-pathogenic isolates of Entamoeba histolytica. Parasitology 1992; 104: 239-246.
12. González-Ruiz A, Ruiz-Palacios G. Entamooeba hartmanni: missing or misidentified. J Infect Dis 1991; 164:612-613.
13. Heckrndorn F, Goran K, Felger P, Voutnasou A, Yapi A, Oettli H, Marti M, Dobler M, Tratore K, Lohourignon L, Lengler C. Species-specific testing of Entamoeba ssp. in area of high endemicity. Trans R Soc Trop Med Hyg 2002; 96: 521-528.
14. Petri W, Haque R, Lyerly D, Vines R. Estimating the impact of amoebiasis on health. Parasitol Today 2000; 16:320-321.
15. Urdaneta H, Cova J, Molina S, Aguirre A, Hernández M. Evaluación inmunológica de cepas de E. histolytica venezolanas. Kasmera 1998; 26:35-49.
16. Raj L, Upcrof T. Clinical significance of the redefinition of the agent of amoebiosis. Rev Latinoam Microbiol 2001; 43:183-187.
17. Mora L, García A, Donato M. Prevalencia del complejo Entamoeba histolytica/Entamoeba dispar en pacientes con síntomas gastrointestinales de diarrea procedentes de Cumaná, Estado Sucre. Kasmera 2005; 33(1):36-45.
18. Organización Panamericana de la Salud. Organización Mundial de la Salud. Atención integrada a las Enfermedades Prevalentes de la Infancia. AIEPI. Reunión sobre el control de las Helmintiasis intestinales en el contexte AIEPI. Octubre 1998: 184.
19. Epidemiología. Boletines Epidemiológicos 2007. Boletin Epidemiológico Semanal. Semana No 19. En www.msps.gob.ve.
20. Moody S, Becker S, Nuchamowitz Y, Mirelman D. Virulent and avirulent Entamoeba histolytica and Entamoeba dispar differ in their cell surface phosphorylated glycolipids. Parasitology 1997; 114:95-104.
21. Diamond, L. Axenic cultivation of Entamoeba histolytica. Science 1961; 134:336-339.
22. Diamond L. Techniques of anexic cultivation of Entamoeba histolytica Schaudinn 1903 and E. histolytica like amebae. J Parasitol 1968; 54:1047-1056.
23. Urdaneta H, Rondon M, Muñoz M, Hernández M. Isolation and axenization of two Entamoeba histolytica strains. GEN 1995;49:23-28.
24. Guimaraes S, Urdaneta H, Silva E, Tavares C. Entamoeba histolytica: Antigenic characterization of axenic strains from Brazil. Rev Inst Med Trop Sao Paulo 1991;33(1):6-11.
25. Edman U, Meraz MA, Rauser S, Agobian N, Meza I. Characterization of an inmunodominant variable surface antigen from pathogenic and nonpathogenic Entamoeba histolytica. J Exp Med 1990; 172: 879-888.
26. Stanley SL. Amoebiasis. Review. Lancet 2003; 361:1025-1034.
27. Stanley SL. Progress towards development of a vaccine for amoebiasis. Review. Clin Microbiol Rev 1997; 10(4):637-649.
28. Stanley SL. Pathophysiology of amoebiasis. Review. Trends Parasitol 2001; 17(6): 280-285.
29. Bhattacharya A, Satish S, Bagchi A, Bhattacharya S Jr. The genoma of Entamoeba histolytica. Int J Parasitol. 2000; 30(4):401-410.
30. Davis PH, Zhang X, Guo J, Townsend RR, Stanley SL. Comparative proteomic analysis of two Entamoeba histolytica strains with different virulence phenotypes identifies peroxiredoxin as an important component of amoebic virulence. Mol Microbiol 2006; 61(6):523-532.
31. Datar RH, Joshi NN. Nucleic acids in diagnosis.Review. Natl Med J India 2001; 14(1):34-42.
32. Cheng XJ, Hughes MA, Huston CD, Loftus B, Gilchrist CA, Lockhart LA, Ghosh S, Miller-Sims V, Mann BJ, Petri WA Jr, Tachibana H. Intermediate subunit of the Gal/GalNAc lectin of Entamoeba histolytica is a member of a gene family containing multiple CXXC sequence motifs. Infect Immun. 2001; 69(9): 5892-5898.
33. Prakash A, Chakraborti A, Mahajan RC, Ganguly AK. DNA polymorphism in north indian isolates of Entamoeba histolytica detected by PGR fingerprinting. Parasitol Res 2002; 88(2):126-129.
34. Aguirre A, Molina S, Urdaneta H, Cova J, Guhl F. Characterization of two Venezuelan Entamoeba histolytica strains using electrophoretic isoenzyme patterns and PGR-SHELA. Arch Med Res 1997; 28:285-287.
35. Mora L. Caracterización molecular y epidemiología de Entamoeba, histolytica y Entamoeba dispar en pacientes con diarrea en Cumaná, Estado Sucre. [Tesis de MSc]. Cumaná: Universidad de Oriente; 2006.
36. Bracho A. Entamoeba histolytica y Entamoeba dispar diagnosticadas mediante reacción en cadena de la polimerasa (PGR) y su correlación con la presencia o no de manifestaciones clínicas en la comunidad de Santa Rosa de Agua. (Tesis de MSc) Maracaibo: Universidad del Zulia, 2007.
37. Araujo J, Urdaneta H, García ME, Díaz-Suárez O, Cheng-Ng R, Estévez J, Cabre ra L. Entamoeba histolytica: Relación entre la evaluación coproparasitologica e Inmunológica en una comunidad Yucpa de la Sierra de Perijá, Estado Zulia Venezuela (Resumen) Memorias de las X Jornadas Científicas "Dra Haydee Parra de Soto". 2001. Maracaibo, Venezuela, p. 123-124.
38. Ayeh-Kumi PF, Ali IM, Lockhart LA, Gilchrist CA, Petri WA Jr, Haque R, Clark CG. Entamoeba histolytica: genetic diversity of clinical isolates from Bangladesh as demonstrated by polymorphisms in the serine-rich gene. Exp Parasitol 2001; 99(2):80-88.
39. Bansal D, Malla N, Mahajan R. Drug resistance in amoebiasis. Review. Indian J Med Res 2006; 123:115-118.
40. Tanyukel M, Petri W. Laboratory diagnosis of amebiasis. Clin Microbiol Rev 2003; 16:713-729.
41. Hanna RM, Dahniya MH, Badr SS, El-Betagy A. Percutaneous catheter drainage in drug-resistant amoebic liver abscess. Trp Med Int Health 2000; 5:578-581.
42. Adagu IS, Nolder D, Warhurst DC, Rossignol JF. In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica, Trichomonas vaginalis. J Antimicrob Chemother 2002; 49: 102-111.
43. Bansal D, Sehgal R, Chawla Y, Mahajan RC, Malla N. In vitro activity of anti-amoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar. Ann Clin Microbiol Antimicrob 2004; 3:27-33.